Phase II study of anti-CD3 x anti-HER2/neu (HERBi) armed activated T cells (ATC) after neoadjuvant chemotherapy in patients with HER2/neu (0-2+)-negative stage II-III breast cancer

被引：0
|
作者：
Bumma, Naresh [1 ]
Kin, Andrew [1 ]
Abrams, Judith [1 ]
Deol, Abhinav [1 ]
Weise, Amy [1 ]
Thakur, Archana [2 ]
Lum, Lawrence [2 ]
机构：
[1] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[2] Univ Virginia, Ctr Canc, Charlottesville, VA 22908 USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P207
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast
    Baselga, J
    Tripathy, D
    Mendelsohn, J
    Baughman, S
    Benz, CC
    Dantis, L
    Sklarin, NT
    Seidman, AD
    Hudis, CA
    Moore, J
    Rosen, PP
    Twaddell, T
    Henderson, IC
    Norton, L
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) : 737 - 744
  • [32] Phase II antibody trial of the bispecific antibody MDX-H210 (anti-HER2/neu x anti-CD64) combined with GM-CSF in patients with advanced prostate and renal cell carcinomas that express HER2/neu.
    James, N
    Atherton, P
    Koletsky, A
    Tchekmedyian, N
    Curnow, R
    BRITISH JOURNAL OF CANCER, 1998, 78 : 19 - 19
  • [33] Targeting of glioblastoma with activated T cells armed with anti-CD3xanti-HER2/neu (HER2Bi) and anti-CD3xanti-EGFR (EGFRBi) bispecific antibodies
    Zitron, I. M.
    Norkina, O.
    Al-Kadhimi, Z.
    Barger, G. R.
    Lum, L. G.
    Mittal, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer.
    Kiewe, P
    Hasmüller, S
    Kahlert, S
    Heinrigs, M
    Rack, B
    Marmé, A
    Korfel, A
    Thiel, E
    Sommer, H
    Untch, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 173S - 173S
  • [35] Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)
    Seyoung Seo
    Min-Hee Ryu
    Young Soo Park
    Ji Yong Ahn
    Yangsoon Park
    Sook Ryun Park
    Baek-Yeol Ryoo
    Gin Hyug Lee
    Hwoon-Young Jung
    Yoon-Koo Kang
    Gastric Cancer, 2019, 22 : 527 - 535
  • [36] Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)
    Seo, Seyoung
    Ryu, Min-Hee
    Park, Young Soo
    Ahn, Ji Yong
    Park, Yangsoon
    Park, Sook Ryun
    Ryoo, Baek-Yeol
    Lee, Gin Hyug
    Jung, Hwoon-Young
    Kang, Yoon-Koo
    GASTRIC CANCER, 2019, 22 (03) : 527 - 535
  • [37] Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: Results of GASTric cancer HER2 reassessment study 3 (GASTHER3).
    Seo, Seyoung
    Ryu, Min-Hee
    Ahn, Ji Yong
    Park, Yangsoon
    Park, Sook Ryun
    Ryoo, Baek-Yeol
    Park, Young Soo
    Lee, Gin Hyug
    Jung, Hwoon-Yong
    Kang, Yoon-Koo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [38] Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients
    Vaishampayan, Ulka
    Thakur, Archana
    Rathore, Ritesh
    Kouttab, Nicola
    Lum, Lawrence G.
    PROSTATE CANCER, 2015, 2015
  • [39] Effect of adding TS-1 to neoadjuvant chemotherapy in HER2-negative, stage II-III breast cancer in a single-arm phase II study
    Lee, S.
    Moon, Y.
    Park, B.
    Kim, S. I.
    Park, S.
    Kim, J.
    Choi, H. J.
    Sohn, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts
    Barbieri, E.
    Piacentini, F.
    Dieci, M. V.
    Ficarra, G.
    Bettelli, S.
    Conte, P.
    Guarneri, V.
    CANCER RESEARCH, 2011, 71
12345